The latest developments on novel agents in the treatment of AML: Updates from #ASCO23 and EHA

Updates on several novel agents in acute myeloid leukemia (AML) were presented during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2023 Hybrid Congress. We are pleased to summarize updates on five novel agents being evaluated to treat patients with AML: iadademstat, ZN-d5, azenosertib, ziftomenib, and olutasidenib.

During ASCO 2023, Fathi¹ presented an update of the FRIDA trial (NCT05546580) investigating iadademstat, previously covered by the AML Hub, plus gilteritinib. Smith² presented an update of the ZN-d5-004C trial (NCT05682170) investigating ZN-d5 and azenosertib. During EHA 2023, Fathi³ presented the findings of the KOMET-001 trial (NCT04067336) studying ziftomenib monotherapy, previously reported by the AML Hub. Zeidan⁴ presented the findings of the KOMET-007 trial (NCT05735184) investigating ziftomenib combination therapy at ASCO 2023. During EHA 2023, Cortes⁵ presented a subgroup analysis from a phase II trial (NCT02719574) investigating olutasidenib, previously covered by the AML Hub. An overview of these trials is detailed in Table 1.

Table 1. Overview of studies presented at ASCO 2023 and EHA 2023*

Iadademstat¹

Iadademstat is a specific, oral, potent, covalent inhibitor of the epigenetic LSD1/KDMA1 enzyme. The phase Ib ongoing FRIDA trial is investigating iadademstat + gilteritinib in adult patients with relapse/refractory (R/R) FLT3-mutated AML. In the dose-escalation portion of this study, up to ~6 patients per dose level will receive iadademstat in combination with gilteritinib. Once pharmacologically active doses are identified, these will be assessed in up to ~14 patients per dose cohort in the dose-expansion portion of this study and monitored for safety and efficacy (Figure 1)

 

This study is planned to open in 15 sites in the U.S. and is currently accruing patients at four sites. The first dose-escalation cohort is completed, with no dose-limiting toxicities.

ZN-d5 and azenosertib²

ZN-d5 is an oral, selective BCL-2 inhibitor, while azenosertib is an oral, highly potent WEE1 inhibitor. The phase I/II ZN-d5-004C trial will assess ZN-d5 and azenosertib in patients aged ≥18 years with AML who are R/R to ≥1 line of therapy. Patients will receive azenosertib monotherapy or ZN-d5 + azenosertib combination therapy (Figure 2). The primary endpoints are adverse events (AEs) and observed dose-limiting toxicities. Secondary endpoints include:

• Rate and duration of remission
• Relapse rate
• Time to relapse
• Plasma pharmacokinetic parameters

This study is currently enrolling at seven centers in the U.S. 

Ziftomenib³

KOMET-001

Ziftomenib is a potent and selective menin-MLL-KMT2A inhibitor.^3,4 The phase I part of phase I/II KOMET-001 trial aimed to identify the recommended phase II dose of ziftomenib and assess the safety of ziftomenib in patients with R/R NPM1-mutated or KMT2A rearranged AML. The analysis presented by Fathi³ at EHA 2023 focused on the phase Ib expansion part of this trial (Figure 3).

 The data cut-off for this analysis was April 12, 2023.

In total, 20 patients were included in phase Ib part of the trial, with a median age of 70.5 years. Of these, 30% of patients had a FLT3 co-mutation, 40% had an IDH1/2 co-mutation, and 20% had both FLT3 and IDH1/2 co-mutations. The median number of prior therapies was three, with 65% of patients previously treated with venetoclax and 20% of patients having had prior stem cell transplantation.

Key findings

Safety analysis revealed that 95% of patients experienced treatment-emergent AEs, including 85% of patients who experienced Grade ≥3 treatment-emergent AEs. In total, 60% of patients experienced treatment-related AEs, of which 30% experienced Grade ≥3 treatment-related AEs. The most common were nausea (20%) and differentiation syndrome (20%).

Ziftomenib was associated with a CR rate of 35%, and the presence of FLT3 and IDH1/2 mutations did not negatively impact response rates (Figure 4).

 The composite CR rate was 40%, while the overall response rate (ORR) was 45%. The median time to first response was 51 days and the median duration of response was 8.2 months. Four of six patients achieving composite CR had negative measurable residual disease. The resistance profile was investigated, demonstrating that the binding affinity of ziftomenib is reduced by Menin^M3271 but not by Menin^T349M. The phase II part of KOMET-001 trial is currently recruiting patients with R/R NPM1-mutated AML.

KOMET-007⁴

The phase Ia/Ib KOMET-007 trial is a two-part dose-escalation and -expansion study investigating the safety, tolerability, and preliminary clinical activity of ziftomenib in combination with non-intensive and intensive chemotherapy in patients with NPM1-mutated or KMT2A-rearranged AML (Figure 5).

 

 

This study is currently enrolling at several sites across the U.S., with more sites to be added.

Olutasidenib⁵

Olutasidenib is an oral, potent, and selective IDH1 inhibitor. This is a subset analysis of 17 patients previously treated with venetoclax combinations from the 2102-HEM-101 trial. Patients received olutasidenib 150 mg twice daily either alone (n = 15) or in combination with azacitidine (n = 2) in a continuous 28-day cycle. The median age of patients in the post-venetoclax cohort was 73 years (range, 65–83 years) and the baseline characteristics are listed in Table 2.

Table 2. Patient characteristics*

Key findings

The ORR was 41% in the entire post-venetoclax cohort, with an ORR of 40% and 50% in the monotherapy and the combination group, respectively. The CR/CR with partial hematologic recovery (CRh) rate was 29.4%, with 23.5% of patients achieving CR. Among patients who received prior venetoclax + azacitidine combination therapy, 50% achieved CR+CRh and 62.5% achieved an ORR. The median duration of CR+CRh has not been reached and is ongoing at 18.5 months (range, 4.8–not reached). Of the patients who were transfusion-dependent at baseline, 56-day transfusion independence was achieved by 25% and 43% of patients who were red blood cell and platelet transfusion-dependent, respectively.

Conclusion

These updates of ongoing trials presented at ASCO and EHA 2023 demonstrate promising novel therapies in the treatment of AML. The phase Ib expansion part of the KOMET-001 trial showed that ziftomenib was well tolerated and associated with significant clinical activity in patients with NPM1-mutated AML.³ In the subgroup analysis from the 2102-HEM-101 trial, olutasidenib was associated with durable remissions and transfusion independence in patients with R/R IDH1-mutated AML. Further findings from these trials will inform the efficacy and safety data on novel agents in the treatment of AML.